Experimental cancer drug halted in early testing phase

NCT ID NCT04762602

Terminated Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety and appropriate dosage of an experimental oral drug called HMPL-306 in people with advanced solid tumors that have a specific genetic change (IDH mutation). The trial enrolled 42 adults whose cancer had progressed after standard treatments. The main goal was to find the highest dose patients could tolerate without severe side effects and to see if the drug showed any early signs of slowing the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Emory University

Atlanta, Georgia, 30322, United States
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital de la Santa creu i Sant Pau

Barcelona, 08025, Spain
Houston Methodist

Houston, Texas, 77030, United States
Sarcoma Oncology Research Center

Santa Monica, California, 90403, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
UPMC Hillman Cancer

Pittsburgh, Pennsylvania, 15232, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Kentucky

Lexington, Kentucky, 40536, United States

Conditions

Explore the condition pages connected to this study.

ISOCITRATE DEHYDROGENASE GENE MUTATION